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Abstract
Objectives: The treatments of limbic and other autoim-
mune encephalitis include immunosuppression, sympto-
matic treatment, and in the case of paraneoplastic
syndromes, appropriate therapy for underlying neoplasms.
When immunotherapy is considered, intravenous immuno-
globulin is one option for treatment, either alone or in
combination with corticosteroids. To date, however, evi-
dence for the use of intravenous immunoglobulin in this
context comes from case series/expert reviews as no con-
trolled trials have been performed. We aimed to analyse the
NHS England Database of intravenous immunoglobulin
usage, which was designed to log use and guide procure-
ment, to explore usage and therapeutic effect of intravenous
immunoglobulin in autoimmune encephalitis in England.
Design: We conducted a retrospective audit and review of
the NHS England Database on intravenous immunoglobulin
use.
Setting: NHS England Database of intravenous immunoglo-
bulin use which covers secondary and tertiary care pre-
scribing and use of intravenous immunoglobulin for all
patients in hospitals in England.
Participants: Hospital in-patients with confirmed or
suspected autoimmune/limbic encephalitis between
September 2010 and January 2017.
Results: A total of 625 patients who were 18 years of age
or older were treated with intravenous immunoglobulin for
autoimmune encephalitis, of whom 398 were determined
as having ‘highly likely’ or ‘definite’ autoimmune/limbic
encephalitis. Ninety-six percent were treated with a
single course of intravenous immunoglobulin. The availabil-
ity and accuracy of reporting of outcomes was very poor,
with complete data only available in 27% of all cases.
Conclusions: This is the first review of data from this unique
national database. Whilst there was evidence for clinical
improvement in many cases of patients treated with intrave-
nous immunoglobulin, the quality of outcome data was
generally inadequate. Methods to improve quality, accuracy
and completeness of reporting are crucial to maximise
the potential value of this resource as an auditing tool.
Keywords
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Introduction
Autoimmune encephalitis is a neuropsychiatric con-
dition usually involving subacute onset of amnesia,
behavioural change and seizures. Some cases are
paraneoplastic, secondary to an immune reaction to
a remote tumour, and some have no identiﬁable
tumour. Many cases are likely antibody-mediated.
The majority of antibodies are directed against neur-
onal cell surface proteins and are likely causative.1
The commonest neuronal cell surface proteins include
the N-methyl, D-aspartate receptor (NMDAR),
LGI1 and the GABAB-receptor. First line immu-
notherapies for these conditions include corticoster-
oids, intravenous immunoglobulin or both. These are
usually more eﬀective in autoimmune encephalitis
associated with neuronal cell surface proteins.1–6
Plasma exchange or immunoadsorption may be
useful treatments, but in many centres their use is
restricted as a second-line agent.7 In the absence of
randomised controlled trials – which are logistically
diﬃcult to carry out in these recently deﬁned condi-
tions – recommendations for treatment come from
observational studies and expert consensus.
Neurological indications account for over 40% of
the total usage of intravenous immunoglobulin.8 In
2015, approximately 4.2 million grams of intravenous
immunoglobulin was used to treat various medical
conditions approved in the Department of Health
Guidelines. Less than 5% of this was used to treat
autoimmune encephalitis, classiﬁed as a ‘grey’ indica-
tion.9 The NHS England Database of intravenous
immunoglobulin usage provides a unique resource to
investigate the use of intravenous immunoglobulin
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across the UK. Considering intravenous immunoglo-
bulin has relatively limited availability depending on
indication, and it costs approximately £5040 for a ﬁve-
day course in a 70 kg patient, the database was estab-
lished to attempt to track intravenous immunoglobulin
use for various conditions across theNHS for contract-
ing and procurement purposes. It was later modiﬁed to
include ‘Outcome’ data tomonitor appropriate use and
potentially serious side eﬀects including thrombo-
embolism and haemolytic anaemia. However, this
was not its initial purpose or design.
Using this database, we aimed to assess outcomes
in cases of autoimmune encephalitis and the propor-
tion of patients who demonstrated favourable out-
comes. We also aimed to assess completeness and
accuracy of data entry by the medical teams on appli-
cation for approval of use of intravenous immunoglo-
bulin in these cases in terms of diagnosis and
longitudinal outcome measures.
Methods
Retrospective, observational, pseudo-anonymised
data were extrapolated from the NHS National
Immunoglobulin Database.8 This database contains,
amongst others, the following relevant ﬁelds
which we extracted: ‘Diagnosis Conﬁdence’; ‘plasma
exchange’; ‘Outcome’; ‘Outcome Result’; ‘Condition
Improved’; ‘Comments’. We applied the search terms
‘encephalitis’; ‘autoimmune encephalitis’; ‘limbic
encephalitis’; ‘antibody-mediated encephalitis’;
‘encephalopathy’. We also searched for cases classi-
ﬁed as ‘other’ because some cases of deﬁned anti-
body-mediated encephalitis or encephalopathy were
misclassiﬁed by ‘freetext’ within this category. We
extracted the data and performed both qualitative
and, where possible, quantitative analyses.
This was considered an audit of use with pseudo-
anonymised data not speciﬁcally requiring research
ethics committee approval prior to commencement.
Results
Between September 2010 and January 2017, a total of
625 patients (328 female) aged between 18 and 102
were identiﬁed as fulﬁlling our search criteria and
having been treated with intravenous immunoglobu-
lin. Diagnoses identiﬁed using our search terms
included: ‘likely encephalitis’; ‘limbic encephalitis’;
‘autoimmune encephalitis’; ‘autoimmune limbic
encephalitis’; ‘anti-NMDA encephalitis’; ‘anti-GAD
encephalitis’; ‘anti-VGKC encephalitis’; ‘encephalop-
athy’. Considering a likely autoimmune aetiology,
193 cases were classiﬁed in the ‘Diagnostic
Conﬁdence’ category as ‘Deﬁnite’, 205 were classiﬁed
as ‘Highly likely’, 77 as ‘possible’ and 150 did not
have information available (ﬁeld left blank). The
data recorded in this ﬁeld were assumed to be the
degree of diagnostic certainty of the treating clin-
icians. However, no actual deﬁnitions of deﬁnite,
probable or possible disease were provided in the
database for these terms.
Of the 625 patients, 15 (2.4%) were treated with
two courses of intravenous immunoglobulin and 7
(1.1%) were treated with three courses over 6–14
months. One patient was treated with ﬁve courses
over two and a half months. Requests for ‘long-
term’ intravenous immunoglobulin treatment were
submitted for 81 patients but no further information
was available and it was not apparent that any more
than one course was given. Fifteen cases were
reported to have been also treated with steroids and
14 were given other immunotherapies (mycopheno-
late in 8; azathioprine in 6). However, data on other
immunotherapy were not available (ﬁelds left blank)
in the remaining 596 (95%) cases. Plasma exchange
use is summarised in Table 1. There was no correl-
ation or information available on whether plasma
exchange was considered or trialled more frequently
in patients who had more than one course of intrave-
nous immunoglobulin.
Outcome data were only available in 167 of the 625
cases (27%; Table 2). Of the 167 patients, 160 had
some clinical and/or cognitive outcome(s) docu-
mented either alone or in combination. These
included free-hand text entries outlined in Table 2.
However, completeness and quality of reporting
varied widely from no information entered (ﬁeld left
blank) to incomplete to uninterpretable/inconclusive.
Of the 167 cases, 11 had autoantibody measurements
entered as an outcome measure (including GAD
(n¼ 1), NMDAR (n¼ 3) and/or VGKC-complex-
antibodies (n¼ 7)). Of these, 7 of 11 reported the
actual titres, one reported ‘positive’ NMDAR-antibo-
dies and one reported ‘present in blood and CSF’,
with two having a blank ﬁeld.
Table 1. Plasma exchange use in patient cohort.
Considered but not available 49 (7.8%)
Considered but not suitable 88 (14%)
‘Not applicable’ 217 (35%)
‘Tried and failed’ 59 (9.4%)
Data not available (field left blank) 212 (34%)
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Forty-three patients had assessments at one time-
point only. The remainder had> 1 assessment docu-
mented, but at diﬀerent time-points and in many cases
the time-points were not clear. Three patients simply
had a drug dosage inserted as an outcome measure.
Three patients had ‘imaging’ inserted as outcome
data, although only one imaging report was quoted.
Twenty-nine patients had ‘seizures’ recorded as an
outcome, but with incomplete reporting on the out-
come result. Twenty-eight had either no improvement
or worsening of their outcome result entered.
However, 58 had documented improvement in symp-
toms, including measures of improvement in mental
status or reduction/control of seizures or reduction in
antibody titres. The remainder had blank ﬁelds,
incomplete, unclear or uninterpretable data entries.
Discussion
intravenous immunoglobulin is a relatively scarce and
certainly expensive resource, accounting for approxi-
mately 0.15% of the whole NHS budget, and it is
vital that it is used appropriately. Compared to
other immunosuppressive therapies intravenous
immunoglobulin is expensive (Table 3), but in combi-
nation with steroids can be rapidly eﬀective and cura-
tive, returning patients to normal functions. The drug
cost takes no account of rapid discharge and return to
society contributions which intravenous immunoglo-
bulin can facilitate. The UK centralised database is
an essential and complete record of intravenous
immunoglobulin prescribing throughout the NHS,
providing commissioners, contracting agencies, regu-
latory bodies and researchers data on national and
regional usage, and a breakdown of its use by condi-
tion and subspecialty.8 The database is mature,
having been in use for over six years. The database
should provide a means of estimating beneﬁt to
patients through the measurement of longitudinal
outcome measures. However, as this review demon-
strates, the quality of data – and information about
outcomes in particular – is inconsistently collected at
best, and for the most part extremely poor.
The aim of this audit was to assess retrospectively
the NHS England data collected for one intravenous
immunoglobulin-indication. The objectives were
many, including: assessing the frequency of autoim-
mune encephalitis treated with intravenous immuno-
globulin, the treatment patterns and parallel therapies
used, the outcomes of treatment (both absolute out-
comes and the range of measures used) and the pres-
entation of data to NHS England Commissioners to
indicate the frequency of disease and intravenous
immunoglobulin response.
The ﬁeld of neuronal cell surface proteins has
moved on in recent times, and rationalisation of
tests – for example using CSF NMDAR-antibody
levels, or LGI1 and CASPR2 testing in preference
to the much less speciﬁc VGKC-complex assay1–4 –
will help more accurately guide intravenous immuno-
globulin usage. However, abolition of an antibody
titre seldom occurs even though the patient recovers
and so this is not an absolute outcome to measure.
In many respects, our audit produced useful out-
comes. We were able to extrapolate an approximate
Table 2. Examples of outcome measures used in database.
Free-hand text entry terms Numbers
‘Clinical Response’/‘Clinical’/‘Clinical
Improvement’
24
Glasgow Coma Scale (GCS) 4
‘Seizures’/‘Reduction in Seizure
Frequency’
29
‘Good Memory’/‘Cognitive Function’/
‘Cognitive Testing’/‘Cognitive
Assessment’/ACE-R/MMSE
42
‘Hallucinations’/‘Improved Mental
State’/‘Abnormal Behaviour’
13
‘Functionality’/modified Rankin scale 7
‘Patient alive’/‘Survival’/RIP 6
Autoantibodies 11
Others 31
Table 3. Illustration of comparative cost of a course of
treatment in acute AE.
Agent Cost for 70 kg patient (excluding
cost of hospital stay) in £GB
and estimated duration and
frequency of treatment
Intravenous
immunoglobulin
5040
Intravenous
methylprednisolone
86.50 (5-day course 1 g daily
Solu-medrol)
Plasma exchange Approximately 5000
Azathioprine 26.38 (1 month azathioprine
200 mg od)
Mycophenolate 197.42 (1 month mycophenolate
mofetil 1 g bd)
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incidence of autoimmune encephalitis of 1/million per
antibody, which compares with previous estimates of
1.7/million.10 In cases where outcome data were avail-
able (27%), intravenous immunoglobulin was shown
to be eﬀective in 39%. Very few patients are regis-
tered on the database as deceased and this probably
reﬂects better treatment in recent years compared to
before they were widely recognised, with a higher
mortality among untreated patients.11 Another
explanation is that patients who died may not have
been recorded in the database at all.
However, a striking feature was the frequency of
poor and incomplete data entry into the database
across all measures. There are several potential rea-
sons for this. Firstly, the database was established
principally to determine usage (both volume and by
institution) to pre-empt and avoid shortages and
potential patient harm, rather than to collect outcome
data properly. The clinical utility of this database is
determined by the quality of the data entered, which
requires the treating physicians to provide data pro-
spectively and after treatment for outcomes. There is
little or no incentive to enter outcome data when
usage is not repeated, i.e. once patients have recov-
ered, died or moved on to other treatment. Often
multiple treatments are used in parallel or serially
and assessing the eﬀect of intravenous immunoglobu-
lin alone is diﬃcult, not least if these co-treatments
are not recorded.
The data are then added by pharmacists who have
little medical or interpretative knowledge of a com-
plex subject. No speciﬁc funds have been provided to
enter the data at a pharmacy level although a small
ﬁnancial pharmacy cost is theoretically built into ser-
vice level agreements. Data are entered by pharma-
cists. No medical portal is provided. And although
free text entry is discouraged with drop down pre-
ﬁlled options, the ‘other’ category was frequently
used. Data entry is generally non-standardised with
variable requirements and acceptability in terms of
forms being granted positive review for processing.
There were a very wide variety of outcome measures
used, making results, even when recorded, not always
comparable.
There are additional limitations to the study. As a
retrospective audit, we were restricted to use pseudo-
anonymised data from the database without access to
patient level information or any ability to interrogate
notes for outcomes other than in our own centre. The
nature of autoimmune encephalitis means that intra-
venous immunoglobulin is often prescribed in one
setting, with ongoing management provided else-
where. And the limitations of the database when rec-
ording outcomes for autoimmune encephalitis do not
necessarily reﬂect those in other conditions, where T
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more standardised pathways to prescription and
monitoring may be available.
It is evident that the current system for recording
data relevant to the prescribing and outcome moni-
toring in autoimmune encephalitis has enormous
potential. However, in its current form it is not able
to fulﬁl the purpose of being a reliable audit tool. In
order to improve the quality of reporting and to
reﬂect true ﬁgures relating to outcomes, systems for
recording these data need to be standardised,
improved and mandated. A data collection system
designed for purpose rather than retrospectively
adapted from another function would improve ease
of collection and consistency. Additional improve-
ments that are likely to improve compliance might
include more ﬂexible portals for clinicians directly
involved in care, systems for including prior or con-
current other immune modifying treatments and the
use of simple approved standardised outcomes which
could be added by members of the primary clinical
team (for example the modiﬁed Rankin scale which
can be retrospectively calculated from notes, or the
standardised set of outcomes recommended at
University College London Hospitals – see Table 4).
Without this, the data will remain unreliable and of
use only at a very low level of resolution. Sir Josiah
Stamp is quoted as saying (often referred to as
Stamp’s Law):
The government are very keen on amassing statistics.
They collect them, add them, raise them to the nth
power, take the cube root and prepare wonderful
diagrams. But you must never forget that every one
of these ﬁgures comes in the ﬁrst instance from the
village watchman, who just puts down what he damn
pleases.
We would hope that with amendments to data collec-
tion requirements, future statistics amassed will
reﬂect accurate use and provide data on the true bene-
ﬁt to patients.
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